| The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms SH Sindrup, LF Gram, K Brøsen, O Eshøj, EF Mogensen Pain 42 (2), 135-144, 1990 | 646 | 1990 |
| CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages J Kirchheiner, K Brøsen, ML Dahl, LF Gram, S Kasper, I Roots, F Sjöqvist, ... Acta Psychiatrica Scandinavica 104 (3), 173-192, 2001 | 575 | 2001 |
| Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study Danish University Antidepressant Group Journal of Affective Disorders 18 (4), 289-299, 1990 | 572 | 1990 |
| The hypoalgesic effect of tramadol in relation to CYP2D6 L Poulsen, L Arendt‐Nielsen, K Brøsen, SH Sindrup Clinical Pharmacology & Therapeutics 60 (6), 636-644, 1996 | 498 | 1996 |
| Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial SH Sindrup, G Andersen, C Madsen, T Smith, K Brøsen, TS Jensen Pain 83 (1), 85-90, 1999 | 484 | 1999 |
| Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention J Hallas, B Harvald, LF Gram, E Grodum, K Brøsen, T Haghfelt, N Damsbo Journal of internal medicine 228 (2), 83-90, 1990 | 477 | 1990 |
| Fluvoxamine is a potent inhibitor of cytochrome P4501A2 K Brøsen, E Skjelbo, BB Rasmussen, HE Poulsen, S Loft Biochemical Pharmacology 45 (6), 1211-1214, 1993 | 445 | 1993 |
| Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine U Jeppesen, LF Gram, K Vistisen, S Loft, HE Poulsen, K Brøsen European journal of clinical pharmacology 51, 73-78, 1996 | 429 | 1996 |
| The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy SH Sindrup, U Bjerre, A Dejgaard, K Brøsen, T Aaes‐Jørgensen, LF Gram Clinical Pharmacology & Therapeutics 52 (5), 547-552, 1992 | 394 | 1992 |
| Clinical significance of the sparteine/debrisoquine oxidation polymorphism K Brøsen, LF Gram European Journal of Clinical Pharmacology 36 (6), 537-547, 1989 | 381 | 1989 |
| The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c MMH Christensen, C Brasch-Andersen, H Green, F Nielsen, P Damkier, ... Pharmacogenetics and genomics 21 (12), 837-850, 2011 | 318 | 2011 |
| Drug related admissions to medical wards: a population based survey. J Hallas, LF Gram, E Grodum, N Damsbo, K Brosen, T Haghfelt, B Harvald, ... British journal of clinical pharmacology 33 (1), 61-68, 1992 | 314 | 1992 |
| Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects L Poulsen, K Brøsen, L Arendt-Nielsen, LF Gram, K Elbaek, SH Sindrup European journal of clinical pharmacology 51, 289-295, 1996 | 310 | 1996 |
| The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors BB Rasmussen, TH Brix, KO Kyvik, K Brøsen Pharmacogenetics and Genomics 12 (6), 473-478, 2002 | 290 | 2002 |
| Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms SH Sindrup, K Brøsen, MGJ Hansen, T Aaes-Jørgensen, KF Overø, ... Therapeutic drug monitoring 15 (1), 11-17, 1993 | 283 | 1993 |
| The relationship between paroxetine and the sparteine oxidation polymorphism SH Sindrup, K Brøsen, LF Gram, J Hallas, E Skjelbo, A Allen, GD Allen, ... Clinical Pharmacology & Therapeutics 51 (3), 278-287, 1992 | 257 | 1992 |
| The pharmacogenetics of codeine hypoalgesia SH Sindrup, K Brøsen Pharmacogenetics and Genomics 5 (6), 335-346, 1995 | 254 | 1995 |
| Recent developments in hepatic drug oxidation implications for clinical pharmacokinetics K Brosen Clinical pharmacokinetics 18, 220-239, 1990 | 248 | 1990 |
| Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine K Brøsen, JG Hansen, KK Nielsen, SH Sindrup, LF Gram European journal of clinical pharmacology 44, 349-355, 1993 | 246 | 1993 |
| Inhibitors of imipramine metabolism by human liver microsomes. E Skjelbo, K Brosen British journal of clinical pharmacology 34 (3), 256-261, 1992 | 216 | 1992 |
Per Damkier確認したメール アドレス: health.sdu.dk
